Alignment of receptor nomenclature with the human genome: Classification of 5-HT1B and 5-HT1D receptor subtypes

被引：231

作者：

Hartig, PR

Hoyer, D

Humphrey, PPA

Martin, GR

机构：

[1] SANDOZ PHARMA AG,PRECLIN RES,CH-4002 BASEL,SWITZERLAND

[2] UNIV CAMBRIDGE,DEPT PHARMACOL,GLAXO INST APPL PHARMACOL,CAMBRIDGE CB2 1QJ,ENGLAND

[3] GLAXOWELLCOME RES & DEV,EUROPEAN CENT NERVOUS SYST CLIN RES,BECKENHAM BR3 3BS,KENT,ENGLAND

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 1996年 / 17卷 / 03期

关键词：

D O I：

10.1016/0165-6147(96)30002-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The continuing rapid progress towards a complete database of structural information on the human genome creates a challenge of ensuring that current schemes for classifying and naming receptors and ion channels effectively integrate this information with functional data to provide unambiguous principles for classification. In this article, Paul Hartig and colleagues review the recent deliberations of the Serotonin Club Nomenclature Committee* and outline a number of its recommendations aimed at encouraging consistency in current and future receptor nomenclature. Based on these principles, the present classification of 5-HT1B and 5-HT1D receptors is reconsidered, and a revised nomenclature for 5-HT1B, 5-HT1D alpha, and 5-HT1D beta receptor subtypes is suggested.

引用

页码：103 / 105

页数：3